FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121120744> ?p ?o ?g. }

• W2121120744 endingPage "3302" @default.
• W2121120744 startingPage "3296" @default.
• W2121120744 abstract "To compare the selective matrix metalloproteinase inhibitor BAY 12-9566 with the nucleoside analog gemcitabine in the treatment of advanced pancreatic cancer.Patients with advanced pancreatic adenocarcinoma who had not previously received chemotherapy were randomly assigned to receive BAY 12-9566 800 mg orally bid continuously or gemcitabine 1,000 mg/m2 administered intravenously on days 1, 8, 15, 22, 29, 36, and 43 for the first 8 weeks, and then days 1, 8, and 15 of each subsequent 28-day cycle. The primary end point was overall survival; secondary end points were progression-free survival, tumor response, quality of life, and clinical benefit. The planned sample size of the study was 350 patients. Two formal interim analyses were planned.The study was closed to accrual after the second interim analysis on the basis of the recommendation of the National Cancer Institute of Canada Clinical Trials Group Data Safety Monitoring Committee. There were 277 patients enrolled onto the study, 138 in the BAY 12-9566 arm and 139 in the gemcitabine arm. The rates of serious toxicity were low in both arms. The median survival for the BAY 12-9566 arm and the gemcitabine arm was 3.74 months and 6.59 months, respectively (P <.001; stratified log-rank test). The median progression-free survival for the BAY 12-9566 and gemcitabine arms was 1.68 and 3.5 months, respectively (P <.001). Quality-of-life analysis also favored gemcitabine.Gemcitabine is significantly superior to BAY 12-9566 in advanced pancreatic cancer." @default.
• W2121120744 created "2016-06-24" @default.
• W2121120744 creator A5003643368 @default.
• W2121120744 creator A5007714289 @default.
• W2121120744 creator A5015598221 @default.
• W2121120744 creator A5016555913 @default.
• W2121120744 creator A5027878340 @default.
• W2121120744 creator A5031504642 @default.
• W2121120744 creator A5044291041 @default.
• W2121120744 creator A5045668242 @default.
• W2121120744 creator A5048698138 @default.
• W2121120744 creator A5050973498 @default.
• W2121120744 creator A5060033945 @default.
• W2121120744 creator A5062767641 @default.
• W2121120744 creator A5063121757 @default.
• W2121120744 creator A5077883560 @default.
• W2121120744 date "2003-09-01" @default.
• W2121120744 modified "2023-10-18" @default.
• W2121120744 title "Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group" @default.
• W2121120744 cites W1854099548 @default.
• W2121120744 cites W1931508686 @default.
• W2121120744 cites W1979390430 @default.
• W2121120744 cites W1984254136 @default.
• W2121120744 cites W1990639292 @default.
• W2121120744 cites W1999784741 @default.
• W2121120744 cites W2001344856 @default.
• W2121120744 cites W2059707463 @default.
• W2121120744 cites W2063931484 @default.
• W2121120744 cites W2075542566 @default.
• W2121120744 cites W2091597922 @default.
• W2121120744 cites W2123344367 @default.
• W2121120744 cites W2162651519 @default.
• W2121120744 cites W2167571044 @default.
• W2121120744 cites W2269021429 @default.
• W2121120744 cites W2281123640 @default.
• W2121120744 cites W4297819854 @default.
• W2121120744 doi "https://doi.org/10.1200/jco.2003.02.098" @default.
• W2121120744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12947065" @default.
• W2121120744 hasPublicationYear "2003" @default.
• W2121120744 type Work @default.
• W2121120744 sameAs 2121120744 @default.
• W2121120744 citedByCount "346" @default.
• W2121120744 countsByYear W21211207442012 @default.
• W2121120744 countsByYear W21211207442013 @default.
• W2121120744 countsByYear W21211207442014 @default.
• W2121120744 countsByYear W21211207442015 @default.
• W2121120744 countsByYear W21211207442016 @default.
• W2121120744 countsByYear W21211207442017 @default.
• W2121120744 countsByYear W21211207442018 @default.
• W2121120744 countsByYear W21211207442019 @default.
• W2121120744 countsByYear W21211207442020 @default.
• W2121120744 countsByYear W21211207442021 @default.
• W2121120744 countsByYear W21211207442022 @default.
• W2121120744 countsByYear W21211207442023 @default.
• W2121120744 crossrefType "journal-article" @default.
• W2121120744 hasAuthorship W2121120744A5003643368 @default.
• W2121120744 hasAuthorship W2121120744A5007714289 @default.
• W2121120744 hasAuthorship W2121120744A5015598221 @default.
• W2121120744 hasAuthorship W2121120744A5016555913 @default.
• W2121120744 hasAuthorship W2121120744A5027878340 @default.
• W2121120744 hasAuthorship W2121120744A5031504642 @default.
• W2121120744 hasAuthorship W2121120744A5044291041 @default.
• W2121120744 hasAuthorship W2121120744A5045668242 @default.
• W2121120744 hasAuthorship W2121120744A5048698138 @default.
• W2121120744 hasAuthorship W2121120744A5050973498 @default.
• W2121120744 hasAuthorship W2121120744A5060033945 @default.
• W2121120744 hasAuthorship W2121120744A5062767641 @default.
• W2121120744 hasAuthorship W2121120744A5063121757 @default.
• W2121120744 hasAuthorship W2121120744A5077883560 @default.
• W2121120744 hasConcept C115880899 @default.
• W2121120744 hasConcept C121608353 @default.
• W2121120744 hasConcept C126322002 @default.
• W2121120744 hasConcept C127413603 @default.
• W2121120744 hasConcept C143998085 @default.
• W2121120744 hasConcept C147176958 @default.
• W2121120744 hasConcept C203092338 @default.
• W2121120744 hasConcept C2780210213 @default.
• W2121120744 hasConcept C2780258809 @default.
• W2121120744 hasConcept C2781182431 @default.
• W2121120744 hasConcept C535046627 @default.
• W2121120744 hasConcept C61943457 @default.
• W2121120744 hasConcept C71924100 @default.
• W2121120744 hasConceptScore W2121120744C115880899 @default.
• W2121120744 hasConceptScore W2121120744C121608353 @default.
• W2121120744 hasConceptScore W2121120744C126322002 @default.
• W2121120744 hasConceptScore W2121120744C127413603 @default.
• W2121120744 hasConceptScore W2121120744C143998085 @default.
• W2121120744 hasConceptScore W2121120744C147176958 @default.
• W2121120744 hasConceptScore W2121120744C203092338 @default.
• W2121120744 hasConceptScore W2121120744C2780210213 @default.
• W2121120744 hasConceptScore W2121120744C2780258809 @default.
• W2121120744 hasConceptScore W2121120744C2781182431 @default.
• W2121120744 hasConceptScore W2121120744C535046627 @default.
• W2121120744 hasConceptScore W2121120744C61943457 @default.
• W2121120744 hasConceptScore W2121120744C71924100 @default.
• W2121120744 hasIssue "17" @default.
• W2121120744 hasLocation W21211207441 @default.
• W2121120744 hasLocation W21211207442 @default.

• next